Blood pressure and left ventricle function in patients treated with anthracyclines;Krevní tlak a funkce levé komory srdeční u pacientů léčených antracykliny

Klinicka Onkologie

Volumn 19, Issue 5, 2006, Pages 269-273

  Balcarkova P ^a   Hrstkova H ^b   Elbl, L ^b   Novakova Z ^c   Zavodna E ^c   Honzikova N ^c   Fiser B ^c  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Anthracyclines; Baroreflex sensitivity; Blood pressure; Cardiotoxicity; Ejection fraction; Fractional shortening

Indexed keywords

ANTHRACYCLINE;

ADOLESCENT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CANCER; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART BEAT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; PRESSORECEPTOR REFLEX;

EID: 33751082934     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kwok JC, Richardson DR: Examination of the mechanisms involved in doxorubicin - mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agent. Molecular Pharmacology, 2004, 65: 181-195
2. Minoti G, Menna P, Salvatorelli E, et al: Antracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 2004, 56: 185-229
3. Butera G, Piciacchia D, Chesa M, et al: Evaluation of late cardiotoxicity of anthracycline in childhood. Minerva Pediatr, 1998, 50: 111-119
4. Geršl V, Bajgar J, Krs O, et al: Changes in cholinesterase activities after daunorubicin administration to rabbits. Human and Experimental Toxicology, 1996, 15: 834-838
5. Lekakis J, Prassopoulos V, Anthnassidias P, et al: Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metiodobenzylguanidine. J Nucl Cardiol, 1996, 3(1): 37-41
6. Steinherz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (J Am Med Assoc). 1991, 266: 1672-77
7. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents. Drug Safety, 2000, 22(4): 236-302
8. Mohta R, Saxena A, Jain Y, et al: Anthracycline Associated Cardiac Toxicity in Children with Malignancies. Indian Pediatrics 2002, 39:549-555
9. Gribbin B, Pickering TG, Sleight P, Peto R: Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971, 24:424-431
10. Zavodna E, Honzikova N, Novakova Z, et al: The development of baroreflex sensitivity at the age between 11 and 21 years. Journal of Hypertension, 2005, 23(2): 286-286
11. Honzíková N, Fišer B, Semrád B: Critical value of baroreflex sensitivity determined by spectral analysis in risk stratification after myocardial infarction. PACE 2000, 23:1965-67
12. La Rovere MT, Specchia G, Mortara A, et al: Baroreflex sensitivity, clinical correlates and cardiovascular mortality among patients with a first myocardial infarction. Circulation 1987, 59:256-262
13. Lábrová R, Honzíková N, Nová ková Z, et al: The relationship between the carotid intima-media thickness, baroreflex sensitivity, variability in blood pressure and heart rate, and ejection fraction in normotensives and hypertensives. Scripta Medica, 2005. 78(2):121-132
14. Wiles HB. Nuclear Cardiology. In: Garson A, Bricker JT, Fisher DJ, et al, eds. The Science and Practice of Pediatric Cardiology, 2nd edition Baltimore 1998: 894-895
15. Boker JS, Kent KM, Bacharach SL et al: Sensitivity, specificity and predictive accurancy of radionuclide cineangiography during exercise in patients with coronary artery disease. Circulation 1979, 60:572-580
16. Kurt D, Ahnberg S, Freed M et al: Quantitative radionuclide angiocardiography: Determination of left ventricular ejection fraction in children. Br Heart J, 1976, 38:726-732
17. Otto CM. Echocardiographic evaluation of left and right ventricular systolic function. In: Otto CM. Textbook of clinical echocardiography. 2nd ed. Philadelphia, WB Saunders Comp, 2000:100-131
18. Honzíková N, Fišer B, Honzík J: Noninvasive determination of baroreflex sensitivity in man by means of spectral analysis. Physiol Res 1992, 41:31-37
19. Al-Kubati MAA, Honzíková N, Semrád B, et al: Baroreflex sensitivity in patients after acute myocardial infarction. Scripta Medica, 1999, 72(8): 337-343
20. Hrstková H, Honzíková N, Závodná E, et al: Krevní tlak u dětí a adolescentů po léčbě zhoubného nádoru. Sborník konference: Ostravské dny podpůrné léčby v onkologü 2004:43
21. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982, 96:133-9
22. Shan K, Lincoff AM, Young JB: Anthracycline-Induced Cardiotoxicity. Ann. Intern. Med.1996, Vol 125: 47-58
23. Kremer LCM, van Dalen EC, Offringa M, et al: Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study. J. of Clinical Oncology.
24. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91:710-7
25. Ferrans VJ: Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978; 62:955-61
26. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989; 7:572-82.
27. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91:710-7.
28. Cortes EP, Lutman G, Wanka J, et al: Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep. 1975; 6:215-25
29. Pratt CB, Ransom JL, Evans WE: Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep. 1978; 62:1381-5
30. Kesavan S, Lincoff AM, Young JB: Anthracycline-Induced Cardiotoxicity. Annals of Internal Medicine 1996, volume 125 Issue 1, 47-58
31. Sakai T, Inagki R, Taniguchi T, et al: Persistent release of noradrenaline caused by anticancer drug 4-epidoxorubicin in rat tail artery in vitro. Eur J Pharmacol, 1998, 356, 1, 25-30
32. Ekholm E, Rantanen V, Bergman M, et al: Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients. Anticancer Research, 2000, 20(3B): 2045-2048
33. Honzíková N, Semrád B, Fišer B, et al: Baroreflex sensitivity determined by spectral method and heart rate variability, and two-years mortality in patients after myocardial infarction. Physiol Res, 2000, 49: 643-650
34. Zavodna E, Honzikova N, Hrstkova H, et al: Development of baroreflex control of heart rate in children and adolescents. The FASEB Journal, 2005, 19(5): 1297-1297
35. Jíra M, Závodná E, Honzíková N, et al: Baroreflex sensitivity as an individual characteristic feature. Phys Res, 2006, 53(3): 349-351
36. Honzíková N, Nováková Z, Zá vodná E, et al: Baroreflex sensitivity in children, adolescents, and young adults with essential and white-coat hypertension. Klin Pediatr 2006, in press
37. Závodná E, Hrstková H, Honzíková N, et al: Autonomous regulation of circulation in children after anthracycline therapy. Scripta Medica, 2002, 74(4): 195-202
38. Honzíková N, Krtička A, Novǎkovǎ Z, et al: A dampening effect of pulse interval variability on blood pressure variations with respect to primary variability in blood pressure during exercise. Physiological Research, 2003, 52:299-309